BioMark Diagnostics, Inc.

Recent News

  • BioMark Scientific Advisor Dr. Donald Miller to Present at the Delaware Valley Drug Metabolism Discussion Group

    Vancouver, British Columbia--(Newsfile Corp. - September 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that on September 29, its strategic scientific advisor Dr. Donald Miller is to present on BioMark's SSAT amantadine assay for the early detection of cancer at the prestigious Delaware Valley Drug Metabolism Discussion Group (DVDMDG).Rashid Ahmed, President and CEO of BioMark, says, "We are pleased to have Dr. Donald Miller present his important work on the...

    2020-09-23 7:30 AM ET
  • BioMark Appoints Dr. Jean-Francois Haince as Strategic Advisor to Guide Its Expansion into Quebec

    Vancouver, British Columbia--(Newsfile Corp. - September 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that it has appointed Dr. Jean-Francois (Jeff) Haince as a strategic advisor to its management team. Rashid Ahmed, President and CEO, says, "We are delighted to welcome Dr. Haince into our advisory team. Jeff brings a pragmatic perspective to our bench strength along with a thorough understanding of engaging within the vibrant biotech ecosystem in Quebec...

    2020-09-16 7:30 AM ET
  • BioMark Team Invited for Full Application for Sparks Grant Competition

    Vancouver, British Columbia--(Newsfile Corp. - September 14, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that 2 of its most recent abstract submissions for the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition have resulted in invitations to submit full applications for funding. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of Health Research - Institute of Cancer Research, and Brain...

    2020-09-14 7:30 AM ET
  • BioMark Team Secures Health Canada Letter of No Objection for Its Glioblastoma Clinical Trial

    Vancouver, British Columbia--(Newsfile Corp. - August 27, 2020) -  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA.The company would like to thank Dr. Marshall Pitz the principal investigator and is the Section Head of Clinical Research at the Research Institute at CancerCare...

    2020-08-27 7:30 AM ET
  • BioMark Diagnostics Expands Research Development in Quebec

    Vancouver, British Columbia--(Newsfile Corp. - August 13, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP, an incubator-accelerator dedicated to tech businesses growth and mentorship."This move highlights BioMark's focus on diagnostic development and technological innovation within the healthcare sector," said Rashid Bux, Chief Executive Officer of BioMark...

    2020-08-13 7:30 AM ET
  • BioMark's Affiliated Company, Bio-Stream Diagnostics Inc. Announces Partnership with Qatar University ML Team for Development of COVID-19 Testing

    Vancouver, British Columbia--(Newsfile Corp. - July 21, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that its affiliated company, Bio-Stream Diagnostics Inc., will be working with University of Qatar's Dr. Somaya Al-Maadeed in the development of its novel COVID-19-detection method, leveraging new generation Raman spectroscopy and the power of machine learning. Raman spectroscopy is a spectroscopic technique typically used to determine vibrational modes of molecules, although rotational and other low-frequency modes of...

    2020-07-21 7:30 AM ET
  • BioMark Diagnostics Inc. Receives Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name "BioMark"

    Vancouver, British Columbia--(Newsfile Corp. - July 16, 2020) -  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name "BioMark". The term "BioMark" was selected by the company in reference to their Biomarker Testing capabilities in the fields of cancer treatment and anti-cancer preparations. Biomarker testing is comprised of a group of...

    2020-07-16 7:30 AM ET
  • BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer

    Vancouver, British Columbia--(Newsfile Corp. - June 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate cancer diagnostic solutions to assist in detecting, monitoring and assessing treatment for cancer early and cost effectively, announced today a peer reviewed scientific publication to support its innovative cancer diagnostic platform that repurposes a U.S. Food and Drug Administration (FDA) off patent drug for a new application.BioMark's team recently published an article...

    2020-06-23 7:30 AM ET